[ad_1]
Ruhul Amin, director of the department, told bdnews24.com on Saturday that SKF had submitted samples of its drugs on Saturday. And Beximco Pharmaceuticals submitted its samples last Wednesday, he said.
Ruhul Amin said that if all goes well, companies will be able to market ‘RemediCV’.
“They will request authorization. If the test results are satisfactory, they will get marketing permission. “
However, Rabbur Reza, the company’s chief operating officer, declined to comment on details of the Beximco drug shipment on Friday. He said they will be able to market the drug this month.
Previously, the Department of Drug Administration did not say anything about drug submission.
In addition to SKF and Beximco, the Department of Drug Administration has allowed Incepta, Square, SKF, Beacon, Health Care, Popular and Opsonin Pharmaceuticals to manufacture the drug in Bangladesh.
RemediciV is made by the American company Gilead Sciences Company. Amid controversy, the US Drug Administration last week approved the use of RMDCV in the treatment of the novel Covid-19 coronavirus in an “emergency.”
As a least developed country, Bangladesh can legally manufacture the drug in accordance with the provisions of the World Trade Organization (WTO) Intellectual Property Rights Agreement or Trade Related Aspects of Intellectual Property Rights (TRIPS).
[ad_2]
